XML 28 R16.htm IDEA: XBRL DOCUMENT
v3.25.3

Note 8 - Accrued Expenses | 9 Months Ended
--- | ---
Sep. 30, 2025
Notes to Financial Statements |
Accounts Payable and Accrued Liabilities Disclosure [Text Block] | Note 8—Accrued Expenses: Accrued expenses consisted of the following (in thousands):
|  | September 30, 2025 |  |  | December 31, 2024 |
Current: |  |  |  |  |  |  |  |
Accrued royalties |  | $ | 8,901 |  |  | $ | 10,169 |
Accrued CRO services |  |  | 2,666 |  |  |  | 1,035 |
Accrued variable consideration |  |  | 11,301 |  |  |  | 10,829 |
Accrued bonus |  |  | 5,647 |  |  |  | 7,976 |
Accrued compensation |  |  | 5,420 |  |  |  | 4,368 |
Accrued other clinical development |  |  | 590 |  |  |  | 935 |
Accrued professional fees |  |  | 454 |  |  |  | 341 |
Accrued legal fees |  |  | 1,049 |  |  |  | 1,095 |
Accrued manufacturing costs |  |  | 917 |  |  |  | 39 |
Other |  |  | 171 |  |  |  | 111 |
|  | $ | 37,116 |  |  | $ | 36,898 |
Long-term: |  |  |  |  |  |  |  |
Accrued other liabilities |  |  | — |  |  |  | 121 |
|  |  | — |  |  |  | 121 |
Totals |  | $ | 37,116 |  |  | $ | 37,019 |
Accrued variable consideration represents estimates of adjustments to product revenue, net for which reserves are established. Accrued royalties represent royalties incurred in connection with the Company’s license agreement with Pfizer. Accrued CRO services, accrued other clinical development expenses, and accrued legal fees represent the Company’s estimates of such costs and are recognized as incurred. Accrued compensation includes severance, commissions and vacation.

X
- Definition The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1 Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureTextBlockAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration